Sun Pharma announced the availability of its treatment for moderate-to-severe plaque psoriasis in the United States, according to a company press release.
Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was approved by the FDA in March for adults who are candidates for systemic therapy or phototherapy. The approval was based on data from the phase 3 reSURFACE clinical development program. Tildrakizumab-asmn is indicated at a dose of 100-mg administered as a subcutaneous injection every 12 weeks, following initial doses at weeks 0 and 4, Sun Pharma reported.
In a pooled analysis of phase 3 studies, data showed that tildrakizumab-asmn demonstrated sustained clinical benefit over a 3-year period and was well-tolerated among patients who were treated. Overall, 9 of 10 patients who achieved 75% PASI75 skin clearance at week 28 after 3 doses of tildrakizumab-asmn 100 mg mainatained their skin clearance after 3 years of treatment, according to the data. Additionally, skin clearance was sustained long-term in 67.6% of patients who had reached PASI 90 after 3 doses.
The most common adverse events include upper respiratory infections, injection site reactions, and diarrhea.

Click to continue reading on Specialty Pharmacy Times.